Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 10/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933567 | 0.93 | CHRM5 (0.42) | CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL16933545 | 0.85 | CHRM5 (0.41) | CHRM5CHRM1CHRM3CHRM2GBA1 | |
| SCHEMBL28657196 | 0.82 | CHRM5 (0.48) | CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL16933499 | 0.81 | HRH3 (0.42) | HRH3NR4A2 | |
| SCHEMBL16933479 | 0.80 | CHRM5 (0.40) | CHRM5CHRM1CHRM3HRH3 | |
| SCHEMBL16933481 | 0.80 | CHRM5 (0.40) | CHRM5CHRM1CHRM3HRH3 | |
| SCHEMBL16933568 | 0.79 | NPY2R (0.38) | — | |
| SCHEMBL16934160 | 0.78 | CHRM5 (0.36) | CHRM5CHRM1CHRM3CHRM2HRH3 | |
| SCHEMBL16933578 | 0.78 | HRH3 (0.38) | CHRM5CHRM1CHRM3HRH3NR4A2 | |
| SCHEMBL16933687 | 0.77 | CHRM5 (0.42) | CHRM5CHRM1CHRM3CHRM2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM5 4860/4885CHRM1 4870/4885CHRM3 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.